Research programme: CCNA2 gene therapy - VentriNova

Drug Profile

Research programme: CCNA2 gene therapy - VentriNova

Alternative Names: Cyclin A2 gene therapy - VentriNova; VN-100; VN-200

Latest Information Update: 26 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VentriNova
  • Class Gene therapies
  • Mechanism of Action Cyclin-dependent kinase modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Myocardial infarction

Most Recent Events

  • 25 Feb 2014 VentriNova is open to partnering opportunities for development of this research programme.
  • 19 Feb 2014 Preclinical trials in Myocardial infarction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top